DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Feasibility Study of Low Level Light Therapy for Prevention of Oropharyngeal Mucositis in Pediatric Transplants Patients

Not Applicable

Completed

Conditions: Oropharyngeal Mucositis
Myeloablative Hematopoietic Cell Transplantation
Low Level Light Therapy

Interventions: Device: Low Level Light Therapy

First Posted Date: 2014-04-22

Last Posted Date: 2017-01-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 13

Registration Number: NCT02119897

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization

Phase 1

Completed

Conditions: Drug Allergy

Interventions: Drug: Omalizumab

First Posted Date: 2014-04-21

Last Posted Date: 2018-02-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT02118987

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck

Phase 1

Completed

Conditions: Carcinoma, Squamous Cell of Head and Neck
Carcinoma of Larynx
Early Invasive Cervical Squamous Cell Carcinoma
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Hypopharyngeal Cancer
Cancer of Nasopharynx

Interventions: Drug: BKM120
Drug: Cisplatin
Radiation: Intensity-modulated radiotherapy (IMRT)

First Posted Date: 2014-04-15

Last Posted Date: 2024-11-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 23

Registration Number: NCT02113878

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Phase 1

Active, not recruiting

Conditions: Relapsed Acute Lymphoblastic Leukemia (ALL)
Refractory Acute Lymphoblastic Leukemia (ALL)
Relapsed Acute Myelogenous Leukemia (AML)
Chronic Myelogenous Leukemia (CML) in Blast Crisis
Relapsed Mixed Lineage Leukemia
Refractory Mixed Lineage Leukemia
Refractory Acute Myelogenous Leukemia (AML)
Relapsed Biphenotypic Leukemia
Refractory Biphenotypic Leukemia

Interventions: Drug: KPT-330

First Posted Date: 2014-03-19

Last Posted Date: 2024-12-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 16

Registration Number: NCT02091245

Locations: 🇺🇸
UCSF, San Francisco, California, United States
🇺🇸
Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

and more 7 locations

A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas

Interventions: Drug: Imprime PGG
Drug: Rituximab

First Posted Date: 2014-03-13

Last Posted Date: 2024-04-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT02086175

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Image-guided Cryoablation of Head, Neck and Spine Tumors

Not Applicable

Completed

Conditions: Malignant Neoplasm of Vertebral Column
Head and Neck Neoplasms

Interventions: Device: Cryoablation
Device: Biopsy

First Posted Date: 2014-03-13

Last Posted Date: 2022-08-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT02085941

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Image-guided Breast Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO)

Not Applicable

Completed

Conditions: Stage I Breast Carcinoma
Stage II Breast Carcinoma

Interventions: Device: intra-operative MRI

First Posted Date: 2014-02-07

Last Posted Date: 2017-01-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 15

Registration Number: NCT02057432

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca

Phase 1

Completed

Conditions: Recurrent Breast Cancer
Metastatic Breast Cancer

Interventions: Drug: Ruxolitinib
Drug: Paclitaxel

First Posted Date: 2014-01-22

Last Posted Date: 2021-04-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT02041429

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Palbociclib
Drug: Aromatase Inhibitor

First Posted Date: 2014-01-20

Last Posted Date: 2025-04-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 162

Registration Number: NCT02040857

Locations: 🇺🇸
MGH/North Shore Cancer Center, Danvers, Massachusetts, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
South Shore Hospital, Weymouth, Massachusetts, United States

and more 7 locations

Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

Phase 2

Terminated

Conditions: Merkel Cell Carcinoma
Skin Cancer

Interventions: Drug: Cabozantinib

First Posted Date: 2014-01-15

Last Posted Date: 2023-05-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 8

Registration Number: NCT02036476

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy